We are live on ! Find out more
ALXN

Alexion Pharmaceuticals
ALXN

Delisted

ALXN was delisted on the 20th of July, 2021.

Back to rankings

547 hedge funds and large institutions have $39.7B invested in Alexion Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 71 funds opening new positions, 255 increasing their positions, 157 reducing their positions, and 84 closing their positions.

New
Increased
Maintained
Reduced
Closed

229% more funds holding in top 10

Funds holding in top 10: 7 → 23 (+16)

62% more repeat investments, than reductions

Existing positions increased: 255 | Existing positions reduced: 157

19% more capital invested

Capital invested by funds: $33.4B → $39.7B (+$6.31B)

3% less funds holding

Funds holding: 565 → 547 (-18)

15% less first-time investments, than exits

New positions opened: 71 | Existing positions closed: 84

65% less call options, than puts

Call options by funds: $164M | Put options by funds: $468M

Holders
547
Holders Change
-18
Holders Change %
-3.19%
% of All Funds
14.74%
Holding in Top 10
23
Holding in Top 10 Change
+16
Holding in Top 10 Change %
+228.57%
% of All Funds
0.62%
New
71
Increased
255
Reduced
157
Closed
84
Calls
$164M
Puts
$468M
Net Calls
-$304M
Net Calls Change
-$297M

Top Buyers

1
BBA
Baker Bros. Advisors
New York
+$1.13B
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$712M
3
Ameriprise
Ameriprise
Minnesota
+$308M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$308M
5
Capital Research Global Investors
Capital Research Global Investors
California
+$271M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$817M
2
VOYA Investment Management
VOYA Investment Management
Georgia
-$174M
3
Citadel Advisors
Citadel Advisors
Florida
-$125M
4
American Century Companies
American Century Companies
Missouri
-$86.2M
5
Prudential Financial
Prudential Financial
New Jersey
-$70.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Brown Advisory
26
Brown Advisory
Maryland
$274M +$252M +1,460,505 +2,735%
Goldman Sachs
27
Goldman Sachs
New York
$257M +$155M +900,791 +174%
BA
28
BlackRock Advisors
Delaware
$243M +$31.3M +181,251 +16%
Millennium Management
29
Millennium Management
New York
$234M +$67.1M +388,617 +43%
DCP
30
DSM Capital Partners
Florida
$228M +$55.6M +322,305 +34%
MAA
31
Managed Account Advisors
New Jersey
$222M +$29.2M +169,272 +16%
Temasek Holdings
32
Temasek Holdings
Singapore
$222M +$212M +1,226,630 New
UBS AM
33
UBS AM
Illinois
$200M +$2.9M +16,818 +2%
Bank of America
34
Bank of America
North Carolina
$199M +$17.4M +100,790 +10%
TG
35
TCW Group
California
$190M -$8.57M -49,648 -5%
GE
36
General Electric
Ohio
$170M +$24.4M +141,500 +18%
Axa
37
Axa
France
$160M +$39.8M +230,704 +35%
Allianz Asset Management
38
Allianz Asset Management
Germany
$155M -$17.6M -101,760 -11%
Legal & General Group
39
Legal & General Group
United Kingdom
$153M +$12.7M +73,438 +10%
JHIU
40
Janus Henderson Investors US
Colorado
$150M +$27.4M +158,847 +24%
First Trust Advisors
41
First Trust Advisors
Illinois
$144M -$27.2M -157,408 -17%
Thrivent Financial for Lutherans
42
Thrivent Financial for Lutherans
Minnesota
$141M +$58.1M +336,510 +76%
BB
43
BB Biotech
Switzerland
$141M +$18.1M +105,000 +16%
TA
44
Teachers Advisors
New York
$131M +$35.5M +205,429 +39%
BlackRock
45
BlackRock
New York
$127M +$7.73M +44,775 +7%
BIM
46
BlackRock Investment Management
Delaware
$125M +$38.3M +222,142 +47%
Alkeon Capital Management
47
Alkeon Capital Management
New York
$124M – – –
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$119M +$6.74M +39,059 +6%
SAM
49
Sectoral Asset Management
Quebec, Canada
$119M +$45.1M +261,201 +66%
GC
50
Guggenheim Capital
Illinois
$117M +$4.98M +28,834 +5%
1
2
3 4 5

ALXN Hedge Fund Activity: Q2 2015 in Review

547 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q2 2015, worth a combined $39.7B — up 19% from $33.4B a quarter earlier.

Sellers outnumbered buyers: 84 funds closed out of ALXN and 71 opened new positions — a net loss of 13 holders — while 157 trimmed existing stakes and 255 added.

The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $1.13B. The largest seller was Fidelity Investments, cutting an estimated $817M.

  • 547 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q2 2015, down from 565 in Q1 2015.
  • Funds reported $39.7B of Alexion Pharmaceuticals stock for Q2 2015, up 19% quarter-over-quarter.
  • 71 funds opened new Alexion Pharmaceuticals positions in Q2 2015 and 84 closed out, a net change of -13 holders.
  • The largest Alexion Pharmaceuticals buyer in Q2 2015 was Baker Bros. Advisors, an estimated $1.13B added.
  • The largest Alexion Pharmaceuticals seller in Q2 2015 was Fidelity Investments, an estimated $817M sold.

Based on aggregated 13F filings for Q2 2015.